Breast cancer (BC) is the most common type of cancer in women and, in most cases, it is hormone-dependent (HD), thus relying on ovarian hormone activation of intracellular receptors to stimulate tumor growth. Endocrine therapy (ET) aimed at preventing hormone receptor activation is the primary treatment strategy, however, about half of the patients, develop resistance in time. This involves the development of hormone independent tumors that initially are ET-responsive (HI), which may subsequently become resistant (HIR). The mechanisms that promote the conversion of HI to HIR tumors are varied and not completely understood. The aim of this work was to characterize the metabolic adaptations accompanying this conversion through the analysis of...
Patients with triple-negative breast cancer (TNBC) are unresponsive to endocrine and anti-HER2 pharm...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
Comparative metabolic profiling of cancerous and normal cells improves our understanding of the fund...
The metabolic characteristics of metastatic and non-metastatic breast carcinomas remain poorly studi...
Breast cancer is the most commonly diagnosed malignancy in women and is the leading cause of cancer-...
Cancer cells adapt their metabolism during tumorigenesis. We studied two isogenic breast cancer cell...
Abstract Breast cancer is the most common cancer with a high rate of mortality and morbidity among w...
Metabolomic strategies have been extensively used to search for biomarkers of disease, including ca...
Background The aims of this study were to characterize the metabolite profiles of triple negative br...
The metabolic crosstalk between tumor cells and tumor-associated macrophages (TAMs) has emerged as a...
Breast cancer is the most commonly diagnosed malignancy in women and is the leading cause of cancer-...
Abstract Background The complex yet interrelated connections between cancer metabolism and oncogenic...
The majority of breast cancers are estrogen receptor positive (ER+) and epidermal growth factor rece...
Metabolic alterations are known to occur with oncogenesis and tumor progression. During malignant tr...
1H NMR analysis was performed on metabolic extracts from a selection of six breast cell lines, inclu...
Patients with triple-negative breast cancer (TNBC) are unresponsive to endocrine and anti-HER2 pharm...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
Comparative metabolic profiling of cancerous and normal cells improves our understanding of the fund...
The metabolic characteristics of metastatic and non-metastatic breast carcinomas remain poorly studi...
Breast cancer is the most commonly diagnosed malignancy in women and is the leading cause of cancer-...
Cancer cells adapt their metabolism during tumorigenesis. We studied two isogenic breast cancer cell...
Abstract Breast cancer is the most common cancer with a high rate of mortality and morbidity among w...
Metabolomic strategies have been extensively used to search for biomarkers of disease, including ca...
Background The aims of this study were to characterize the metabolite profiles of triple negative br...
The metabolic crosstalk between tumor cells and tumor-associated macrophages (TAMs) has emerged as a...
Breast cancer is the most commonly diagnosed malignancy in women and is the leading cause of cancer-...
Abstract Background The complex yet interrelated connections between cancer metabolism and oncogenic...
The majority of breast cancers are estrogen receptor positive (ER+) and epidermal growth factor rece...
Metabolic alterations are known to occur with oncogenesis and tumor progression. During malignant tr...
1H NMR analysis was performed on metabolic extracts from a selection of six breast cell lines, inclu...
Patients with triple-negative breast cancer (TNBC) are unresponsive to endocrine and anti-HER2 pharm...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
Comparative metabolic profiling of cancerous and normal cells improves our understanding of the fund...